sr141716 has been researched along with Chemical Dependence in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 15 (55.56) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Fantegrossi, WE; Hiranita, T; Wilson, CD | 1 |
| Fantegrossi, WE; Wilson, CD; Zheng, F | 1 |
| Soler-Cedeno, O; Xi, ZX | 1 |
| Kinsey, SG; Poklis, JL; Trexler, KR; Vanegas, SO | 1 |
| Eiler, WJA; Gleason, SD; Smith, JL; Witkin, JM | 1 |
| Abdullah, R; Cravatt, BF; Kinsey, SG; Lichtman, AH; Ramesh, D; Selley, DE; Wise, LE | 1 |
| Baldaia, MA; Berro, LF; Frussa-Filho, R; Hollais, AW; Longo, BM; Marinho, EA; Oliveira-Lima, AJ; Patti, CL; Santos, R; Takatsu-Coleman, AL; Wuo-Silva, R; Yokoyama, TS | 1 |
| Fang, Q; Li, D; Li, F; Liu, Y; Lu, L; Wang, J; Zhao, M | 1 |
| Beardsley, PM; McMahon, LR; Thomas, BF | 1 |
| Goldberg, SR; Justinova, Z; Panlilio, LV | 1 |
| Bagdy, G; Hunyady, L; Juhasz, G; Lazary, J | 1 |
| Lupica, CR; Riegel, AC | 1 |
| Carai, MA; Colombo, G; Gessa, GL | 1 |
| Goldberg, SR; Justinova, Z; Redhi, GH; Solinas, M; Tanda, G | 1 |
| Ben-Ari, Y; Bernard, C; Freund, TF; Gozlan, H; Milh, M; Morozov, YM | 1 |
| De Vries, TJ; Schoffelmeer, AN | 1 |
| Beardsley, PM; Thomas, BF | 1 |
| Cossu, G; Deiana, S; Fadda, P; Fattore, L; Fratta, W; Melis, V; Spano, MS | 1 |
| Harloe, JP; Lichtman, AH; Martin, BR; Varvel, SA; Wilson, DM | 1 |
| Halford, JC; Harrold, JA; Kirkham, TC; Tucci, SA | 1 |
| Bifulco, M; Gazzerro, P; Grimaldi, C; Pisanti, S; Santoro, A | 1 |
| De Vries, TJ; Pattij, T; Schoffelmeer, AN; Wiskerke, J | 1 |
| Aceto, MD; Martin, BR; Razdan, RK; Scates, SM | 1 |
| Stahl, SM | 1 |
| Di Chiara, G; Loddo, P; Tanda, G | 1 |
| Beardsley, PM; Martin, BR | 1 |
| Bilbao, A; Koob, GF; Navarro, M; Roberts, AJ; Rodríguez de Fonseca, F | 1 |
12 review(s) available for sr141716 and Chemical Dependence
| Article | Year |
|---|---|
Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge.
Topics: Cannabinoid Receptor Antagonists; Humans; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders | 2022 |
Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders.
Topics: Animals; Brain; Dopamine; Humans; Neural Pathways; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Reward; Rimonabant; Substance-Related Disorders | 2009 |
Drug addiction.
Topics: Animals; Behavior, Animal; Brain; Cannabinoid Receptor Modulators; Cannabinoids; Humans; Piperidines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Reinforcement Schedule; Reward; Rimonabant; Substance-Related Disorders | 2009 |
Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists.
Topics: Animals; Anti-Obesity Agents; Genetic Testing; Humans; Obesity; Piperidines; Polymorphism, Genetic; Precision Medicine; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders | 2011 |
Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.
Topics: Animals; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Dopamine; Dronabinol; Endocannabinoids; Humans; Mesencephalon; Neurons; Piperidines; Pyrazoles; Reward; Rimonabant; Signal Transduction; Substance-Related Disorders; Ventral Tegmental Area | 2005 |
Rimonabant: the first therapeutically relevant cannabinoid antagonist.
Topics: Animals; Body Weight; Cannabinoids; Eating; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders | 2005 |
Cannabinoid CB1 receptors control conditioned drug seeking.
Topics: Animals; Conditioning, Psychological; Disease Models, Animal; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Substance-Related Disorders | 2005 |
Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders.
Topics: Animals; Disease Models, Animal; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders | 2005 |
An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives.
Topics: Animals; Brain; Cannabinoid Receptor Modulators; Disease Models, Animal; Endocannabinoids; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Reward; Rimonabant; Secondary Prevention; Substance Withdrawal Syndrome; Substance-Related Disorders | 2007 |
Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation.
Topics: Animals; Cannabinoid Receptor Modulators; Endocannabinoids; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Smoking Cessation; Substance-Related Disorders | 2006 |
Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.
Topics: Anti-Obesity Agents; Antineoplastic Agents; Body Weight; Humans; Neurodegenerative Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation; Substance-Related Disorders | 2007 |
The role of CB1 receptors in psychostimulant addiction.
Topics: Amphetamine-Related Disorders; Amphetamines; Animals; Association Learning; Brain; Cannabinoid Receptor Modulators; Cannabinoids; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Humans; Mice; Motivation; Neuronal Plasticity; Neurotransmitter Agents; Piperidines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders | 2008 |
15 other study(ies) available for sr141716 and Chemical Dependence
| Article | Year |
|---|---|
Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal.
Topics: Amides; Animals; Cannabinoid Receptor Agonists; Cannabinoids; Humans; Hypothermia; Indazoles; Male; Mice; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders; Tremor; Valine | 2022 |
Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice.
Topics: Animals; Benzodiazepines; Cannabinoid Receptor Agonists; Cannabinoids; Convulsants; Diazepam; Electroencephalography; Humans; Indazoles; Indoles; Male; Mice; Naphthalenes; Pentylenetetrazole; Receptor, Cannabinoid, CB1; Rimonabant; Seizures; Substance-Related Disorders; Valine | 2022 |
The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice.
Topics: Animals; Cannabinoids; Dronabinol; Drug Tolerance; Indazoles; Locomotion; Male; Mice; Mice, Inbred C57BL; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders; Tandem Mass Spectrometry | 2020 |
A medium throughput rodent model of relapse from addiction with behavioral and pharmacological specificity.
Topics: Amino Acids; Animals; Behavior, Addictive; Behavior, Animal; Bridged Bicyclo Compounds, Heterocyclic; Cannabinoid Receptor Antagonists; Conditioning, Operant; Drug Discovery; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Extinction, Psychological; Feeding Behavior; Male; Models, Animal; Pyridines; Rats; Rats, Sprague-Dawley; Recurrence; Rimonabant; Self Administration; Substance-Related Disorders; Thiazoles | 2019 |
Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arachidonic Acids; Benzodioxoles; Brain Chemistry; Cyclohexanols; Diclofenac; Dose-Response Relationship, Drug; Dronabinol; Drug Tolerance; Endocannabinoids; Glycerides; Guanosine 5'-O-(3-Thiotriphosphate); Male; Mice; Mice, Inbred C57BL; Monoacylglycerol Lipases; Pain Measurement; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Stomach Ulcer; Substance Withdrawal Syndrome; Substance-Related Disorders | 2013 |
Effects of rimonabant on the development of single dose-induced behavioral sensitization to ethanol, morphine and cocaine in mice.
Topics: Akathisia, Drug-Induced; Animals; Animals, Outbred Strains; Anxiety; Cannabinoid Receptor Antagonists; Central Nervous System Depressants; Cocaine; Depression; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Ethanol; Male; Mice; Morphine; Motor Activity; Narcotics; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders | 2015 |
Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.
Topics: Animals; Behavior, Animal; Conditioning, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Extinction, Psychological; Injections, Intraperitoneal; Ketamine; Male; Piperidines; Psychotropic Drugs; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Recurrence; Rimonabant; Substance-Related Disorders | 2008 |
The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cocaine; Endocannabinoids; Infusions, Intravenous; Male; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptor, Cannabinoid, CB1; Reinforcement, Psychology; Rimonabant; Saimiri; Self Administration; Stereoisomerism; Substance-Related Disorders | 2005 |
Altering cannabinoid signaling during development disrupts neuronal activity.
Topics: Animals; Brain; Cannabinoid Receptor Modulators; Cannabis; Electrodes; Electrophysiology; Female; Hippocampus; Immunohistochemistry; Male; Microscopy, Electron; Neurons; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, GABA-A; Rimonabant; Signal Transduction; Substance-Related Disorders; Time Factors | 2005 |
SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice.
Topics: Animals; Cannabis; Male; Mice; Mice, Inbred ICR; Piperidines; Pyrazoles; Rimonabant; Substance Withdrawal Syndrome; Substance-Related Disorders | 2006 |
Anandamide, an endogenous cannabinoid, has a very low physical dependence potential.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Cannabinoids; Dose-Response Relationship, Drug; Endocannabinoids; Male; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant; Substance Withdrawal Syndrome; Substance-Related Disorders | 1998 |
Getting stoned without inhaling: anandamide is the brain's natural marijuana.
Topics: Arachidonic Acids; Brain; Brain Chemistry; Cannabinoids; Endocannabinoids; Euphoria; Humans; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance-Related Disorders | 1998 |
Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
Topics: Animals; Behavior, Animal; Cannabinoids; Dopamine; Dronabinol; Hallucinogens; Male; Microdialysis; Nucleus Accumbens; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome; Substance-Related Disorders | 1999 |
Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
Topics: Animals; Dose-Response Relationship, Drug; Dronabinol; Male; Piperidines; Psychotropic Drugs; Pyrazoles; Rats; Rats, Long-Evans; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Substance Withdrawal Syndrome; Substance-Related Disorders | 2000 |
Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers.
Topics: Alcoholism; Animals; Cannabinoids; Conditioning, Operant; Ethanol; Male; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Self Administration; Substance-Related Disorders | 1999 |